AveXis (AVXS): World Muscle Society Data Supports Remarkable Efficacy In Infants - BMO

October 10, 2016 6:49 AM EDT
Get Alerts AVXS Hot Sheet
Price: $46.61 +3.60%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade AVXS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of AveXis (NASDAQ: AVXS) since he believes data presented at the International Congress of the World Muscle Society continue to support AVXS-101's remarkable efficacy in infants with type 1 SMA.

The comparison of '101's data to Nusinersen's Phase 2 trial points to more motor milestones being achieved with '101, likely driven by more rapid induction of SMN protein expression to prevent motor neuron loss. The analyst believes AVXS's next key catalyst is feedback on the design of the Phase 3 trial (expected in late October/early November).

No change to the price target of $52 based on a DCF of 2017-2025E FCF, discounted 17.5% with a 4% terminal multiple.

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $47.51 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital, S1

Add Your Comment